Diversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. Increasing patient representation in clinical trials not only makes…

The pursuit of better healthcare for all has many obstacles. Achieving a state where everyone has fair access to healthcare is a massive endeavor with many stakeholders. It requires addressing…

Clinical trials serve as the bedrock for advancements in medicine, guiding the development of new treatments and therapies. However, a critical issue plaguing these trials is the lack of…

Medical Affairs plays an essential role in evidence-based medicine, disease education, and driving better outcomes. Their knowledge is crucial as medications become more specialized and complex. They enable healthcare…

How will AI impact clinical trials? Will FDA legislation improve diversity? What platforms will key opinion leaders adopt? Every year, we take a look at annual predictions to help life…

The life sciences sector stands on the brink of a new era marked by the confluence of artificial intelligence (AI) and biomedicine. With President Biden’s recent Executive Order on AI,…

As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of inclusive clinical trial recruitment cannot be overlooked. With the rise of digital health and…

In an October 2023 report, BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical…

The life sciences industry, characterized by stringent regulations, vast data sets, and the critical nature of its decisions, is increasingly turning to Artificial Intelligence (AI) for solutions. AI has the…

In medical affairs, building and managing relationships with key opinion leaders (KOLs) is a critical component of successful product launches and long-term growth. But in today's highly regulated environment,…